FDA AdCom to question efficacy and safety concerns with Eli Lilly’s Alzheimer’s drug
The FDA is looking to ask questions about a change of primary endpoint, treatment cessation and mortality reporting from the donanemab trial.
The FDA is looking to ask questions about a change of primary endpoint, treatment cessation and mortality reporting from the donanemab trial.
What's Your Reaction?
